EMEA-003357-PIP01-22 - paediatric investigation plan

nemvaleukin alfa

Key facts

• Active substance:
  nemvaleukin alfa
• Therapeutic area:
  Oncology
• Decision number:
  P/0403/2023
• PIP number:
  EMEA-003357-PIP01-22
• Pharmaceutical form(s):
  Powder and solvent for solution for injection
• Condition(s) / indication(s):
  • Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue)
  • Treatment of malignant neoplasms of the lymphoid tissue
• Route(s) of administration:
  Intravenous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  27/10/2023
• Compliance check done:
  No

Decision

P/0403/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nemvaleukin alfa (EMEA-003357-PIP01-22)

Adopted Reference Number: EMA/400609/2023